Navigation Links
Bringing New Cell Therapies to Market Requires Top-Notch Logistics and Operational Efficiency
Date:1/24/2013

Rockville, Maryland (PRWEB) January 24, 2013

(January 22nd, 2013) — Fisher BioServices, the world’s leading provider of biospecimen storage, cell therapy logistics and related clinical trial services, announced today that Mr. Dan O’Donnell, Associate Director of Cell Therapy Logistics at Fisher BioServices, and Mr. Bruce C. Simpson, Director of Commercial Operations at Fisher BioServices, will be presenting at the 2013 Phacilitate Cell & Gene Therapy Forum, January 28-30, in Washington, DC. This year’s Forum focuses on bringing therapeutics “From Promise to Products” and features presentations and roundtable discussions on positioning new cell and gene therapies for commercial success.

Companies with cell-based therapies nearing clinical trials and FDA approval face the challenge of transporting their product in compliance with FDA requirements for cold chain / chain of custody documentation. Mr. O’Donnell and Mr. Simpson are recognized industry experts on the handling and distribution of gene and cell-based therapies, and will be sharing the latest innovations on the distribution of cell-based products and regenerative medicines from the manufacturer to the patient, while complying with all applicable Title 21 CFR criteria.

The critical issues of commercial viability will be addressed in the first plenary session, and will include valuing cell therapies, reimbursement in the current healthcare environment, and other factors that may influence a product’s commercial success, including distribution systems.

During this session, Mr. O’Donnell will outline the variables that must be considered during every point of transfer in the delivery of cell therapies to the patient, and will discuss the challenges and technical considerations involved in moving cryogenically frozen products around the world.
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. ORNL wins 9 R&D 100s, bringing total to 173
2. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
3. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
4. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
5. BioRestorative Therapies Retains KCSA Strategic Communications as Investor Relations Counsel
6. BioRestorative Therapies Obtains $2.1 Million in 2012 Private Financing
7. BioRestorative Therapies Announces Closing of License Agreement for Adult Stem Cell Disc/Spine Procedure
8. BioRestorative Therapies Announces Next Generation of Stem Cell Disc Delivery Device
9. CNIO researchers describe a new target for developing anti-angiogenic and anti-tumoral therapies
10. BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah
11. CSL Biotherapies Awarded US Government Contract for Influenza Pandemic Preparedness and Response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 /PRNewswire/ ... Bureau presents Innovative Drug Delivery ... Technology Licensing Opportunities for Generic ... There are more ... release drugs approved all over ...
(Date:6/19/2013)... India’s vast and growing population means ... up to a billion dollars per year by ... taking serious action to better regulate and oversee ... will examine:, ,     Recent changes in ... long term impacts ,     Foreseeable opportunities ...
(Date:6/19/2013)... 18, 2013 A new look at ... and other trends will highlight technical sessions at ... fall. In its 33rd year, the three-day event is ... of key suppliers, approximately 100 technical presentations and numerous ... international society for optics and photonics , the meeting ...
(Date:6/19/2013)... Adding to their already extensive supply ... Simport’s Dropette® and Heathrow Scientific disposable plastic ... basic biology, chemistry and any type of liquid handling ... 35 years, Simport has been supplying the science community ... the Simport Dropette®. Simport’s Dropette® is a one-piece ...
Breaking Biology Technology:Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 2Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 3‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 3Leading Pipette Distributor Pipette.com Now Stocks Transfer Pipettes: Simport’s Dropette and Heathrow Scientific Disposable Plastic Transfer Pipettes 2
... RUTHERFORD, N.J. , Feb. 10 Cambrex Corporation (NYSE: ... December 31, 2009 . , Highlights , ... sales decreased 15.8% compared to fourth quarter 2008.  For the full year ... foreign currency. EBITDA was $9.4 million in the fourth ...
... , , ... Oramed,Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ), a developer,of alternative drug ... , Ph.D., was chosen to lecture at the Third,International Conference on ... Basel, Switzerland on February 11, 2010 . Dr. Kidron,will ...
... , PLANTATION, Fla. and ... Biotechnology Inc., a full service Contract Biomanufacturing Company ... agents, jointly announced today their collaborative agreement on ... customer projects in Nuclear Medicine involving Chelation, Bioconjugation ...
Cached Biology Technology:Cambrex Reports Fourth Quarter and Full Year 2009 Results 2Cambrex Reports Fourth Quarter and Full Year 2009 Results 3Cambrex Reports Fourth Quarter and Full Year 2009 Results 4Cambrex Reports Fourth Quarter and Full Year 2009 Results 5Cambrex Reports Fourth Quarter and Full Year 2009 Results 6Cambrex Reports Fourth Quarter and Full Year 2009 Results 7Cambrex Reports Fourth Quarter and Full Year 2009 Results 8Cambrex Reports Fourth Quarter and Full Year 2009 Results 9Cambrex Reports Fourth Quarter and Full Year 2009 Results 10Cambrex Reports Fourth Quarter and Full Year 2009 Results 11Cambrex Reports Fourth Quarter and Full Year 2009 Results 12Cambrex Reports Fourth Quarter and Full Year 2009 Results 13Cambrex Reports Fourth Quarter and Full Year 2009 Results 14Cambrex Reports Fourth Quarter and Full Year 2009 Results 15Oramed's Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland 2Oramed's Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland 3Goodwin Biotechnology Inc. and Macrocyclics Announce Collaboration 2
(Date:6/19/2013)... of Pittsburgh has developed antibacterial compounds, derived from ... potential treatments for drug-resistant bacterial infections and appear ... quite small, making them inexpensive and easy to ... 2013 issue of the journal Antimicrobial Agents ... probable applications will likely be the chronic bacterial ...
(Date:6/19/2013)... , June 19, 2013 MedNet ... in clinical study management systems, is pleased to announce ... be held June 23-27 in Boston ... MedNet, a recognized leader in cloud-based eClinical solutions, has ... will be showcasing iMedNet™ EDC , ...
(Date:6/19/2013)... is the most potent physiological anabolic agent for ... synthesis of lipids, protein and carbohydrates, and inhibiting ... It also plays a major role in stimulating ... is metabolized and removed from the blood following ... molecular mechanisms by which insulin regulates glucose uptake ...
Breaking Biology News(10 mins):HIV-derived antibacterial shows promise against drug-resistant bacteria 2MedNet Solutions To Spotlight iMedNet EDC At The 49th DIA Annual Meeting 2Breakthrough research of essential molecule reveals important targets in diabetes and obesity 2
... and likely to die of - heart disease compared ... are to blame, according to a new University of Leicester ... Maciej Tomaszewski, New Blood Lecturer in Cardiovascular Medicine in the ... that this "male disadvantage" may be related to the sex-specific ...
... an agreement was reached by the Alliance for a ... sales restrictions on "competitive foods" such as soft drinks ... say limiting the availability of soft drinks at school ... elementary school children. In a study of more ...
... Tech have used skin cells to create artificial bones ... into other tissues such as tendons or ligaments. The ... softer tissue rather than the sudden shift of previously ... and allowing them to handle weight more successfully. The ...
Cached Biology News:Sex hormones link to heart risk 2Engineers create bone that blends into tendons 2
UNIVERSAL SCORECARD DNA, 1 EA. * Category: Reagents/Consumables....
mitochondrial proteins (human heart) for 2-D gel electrophoresis *5 mg/mL*...
... GeneMaths XT is undoubtedly the most complete ... advanced concept of layers and subsets makes ... layers for different data outputs, for example ... etc., as well as different subsets of ...
...
Biology Products: